FILING ANALYSIS · TUESDAY, NOVEMBER 10
EXAGEN INC. XGN — 8-K: Results of Operations and Financial Condition
positive
Exagen Inc. reported a 7% increase in revenue to $18.4 million and a 30% improvement in adjusted EBITDA loss, with a reiterated full-year 2026 revenue guidance of $72 million to $75 million. The company's financial performance and pipeline development efforts, including the upcoming launch of its myositis offering, are notable positives.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →